Literature DB >> 16788103

Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.

Junling Liu1, Malinda E Fitzgerald, Michael C Berndt, Carl W Jackson, T Kent Gartner.   

Abstract

Botrocetin (bt)-facilitated binding of von Willebrand factor (VWF) to the platelet membrane glycoprotein (GP) Ib-IX-V complex on platelets in suspension initiates a signaling cascade that causes alphaIIbbeta3 activation and platelet aggregation. Previous work has demonstrated that bt/VWF-mediated agglutination activates alphaIIbbeta3 and elicits ATP secretion in a thromboxane A2 (TxA2)-dependent manner. The signaling that results in TxA2 production was shown to be initiated by Lyn, enhanced by Src, and propagated through Syk, SLP-76, PI3K, PLCgamma2, and PKC. Here, we demonstrate that the signaling elicited by GPIb-mediated agglutination that results in TxA2 production is dependent on Bruton tyrosine kinase (Btk). The results demonstrate that Btk is downstream of Lyn, Syk, SLP-76, and PI3K; upstream of ERK1/2, PLCgamma2, and PKC; and greatly enhances Akt phosphorylation. The relationship(s), if any, between ERK1/2, PLCgamma2, and PKC were not elucidated. The requirement for Btk and TxA2 receptor function in GPIb-dependent arterial thrombosis was confirmed in vivo by characterizing blood flow in ferric chloride-treated mouse carotid arteries. These results demonstrate that the Btk family kinase, Tec, cannot provide the function(s) missing because of the absence of Btk and that Btk is essential for both bt/VWF-mediated agglutination-induced TxA2 production and GPIb-dependent stable arterial thrombus formation in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788103      PMCID: PMC1895591          DOI: 10.1182/blood-2006-01-011817

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.

Authors:  A Oda; Y Ikeda; H D Ochs; B J Druker; K Ozaki; M Handa; T Ariga; Y Sakiyama; O N Witte; M I Wahl
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

2.  Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors.

Authors:  D Wang; J Feng; R Wen; J C Marine; M Y Sangster; E Parganas; A Hoffmeyer; C W Jackson; J L Cleveland; P J Murray; J N Ihle
Journal:  Immunity       Date:  2000-07       Impact factor: 31.745

3.  Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk.

Authors:  K Saito; A M Scharenberg; J P Kinet
Journal:  J Biol Chem       Date:  2001-01-30       Impact factor: 5.157

4.  Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.

Authors:  H Ni; C V Denis; S Subbarao; J L Degen; T N Sato; R O Hynes; D D Wagner
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

5.  Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis.

Authors:  S Konstantinides; J Ware; P Marchese; F Almus-Jacobs; D J Loskutoff; Z M Ruggeri
Journal:  J Thromb Haemost       Date:  2006-09       Impact factor: 5.824

6.  Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo.

Authors:  Christophe Dubois; Laurence Panicot-Dubois; Glenn Merrill-Skoloff; Bruce Furie; Barbara C Furie
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

7.  Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta.

Authors:  A D Munday; M C Berndt; C A Mitchell
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

8.  Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin alpha IIbbeta 3. Studies in human platelets ans transfected Chinese hamster ovary cells.

Authors:  C L Yap; S C Hughan; S L Cranmer; W S Nesbitt; M M Rooney; S Giuliano; S Kulkarni; S M Dopheide; Y Yuan; H H Salem; S P Jackson
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

9.  Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets.

Authors:  Analia Garcia; Todd M Quinton; Robert T Dorsam; Satya P Kunapuli
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

10.  Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIbbeta3- and aggregation-independent manner.

Authors:  Junling Liu; Tamara I Pestina; Michael C Berndt; Carl W Jackson; T Kent Gartner
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

View more
  46 in total

1.  Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl(3)-induced occlusive thrombus formation in the inferior vena cava of mice.

Authors:  M V Joglekar; Jerry Ware; Jin Xu; Malinda E C Fitzgerald; Theodore Kent Gartner
Journal:  Platelets       Date:  2012-06-21       Impact factor: 3.862

Review 2.  Signaling during platelet adhesion and activation.

Authors:  Zhenyu Li; M Keegan Delaney; Kelly A O'Brien; Xiaoping Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 3.  How will B-cell-receptor-targeted therapies change future CLL therapy?

Authors:  Jeffrey A Jones; John C Byrd
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

Review 4.  New Concepts and Mechanisms of Platelet Activation Signaling.

Authors:  Brian Estevez; Xiaoping Du
Journal:  Physiology (Bethesda)       Date:  2017-03

Review 5.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

Review 6.  Chronic lymphocytic leukemia therapy: new targeted therapies on the way.

Authors:  Candida Vitale; Jan A Burger
Journal:  Expert Opin Pharmacother       Date:  2016-04-12       Impact factor: 3.889

Review 7.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

8.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.

Authors:  Rachel A Rigg; Joseph E Aslan; Laura D Healy; Michael Wallisch; Marisa L D Thierheimer; Cassandra P Loren; Jiaqing Pang; Monica T Hinds; András Gruber; Owen J T McCarty
Journal:  Am J Physiol Cell Physiol       Date:  2015-12-09       Impact factor: 4.249

10.  Platelet glycoprotein Ib alpha supports experimental lung metastasis.

Authors:  Shashank Jain; Masahiko Zuka; Jungling Liu; Susan Russell; Judith Dent; José A Guerrero; Jane Forsyth; Brigid Maruszak; T Kent Gartner; Brunhilde Felding-Habermann; Jerry Ware
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.